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CObjective: Drug exposure misclassification may occur in administra-
tive databases when individuals obtain nonreimbursed drugs by pay-
ing “out-of-pocket” or via alternative drug coverage plans. We exam-
ined the apparent association between oral antidiabetic therapy and
mortality by simulating the effects of restrictive drug coverage policies.
Methods: Population-based cohort study of 12,272 new patients using
oral antidiabetic agents were identified using the administrative data-
bases of Saskatchewan Health, 1991 to 1996. We randomly misclassi-
fied 0% [base case], 10%, 25%, and 50% of known patients taking met-
formin according to either overt drug exposure (e.g., metformin users
switched to nonusers) or time of metformin initiation (e.g., delayed
capture of exposure); thereby simulating the use of a “non-formulary”
or “special authorization” policy, respectively. We also simulated an
age-dependent coverage policy, mimicking a policy restricted to
seniors. Results: Metformin use was associated with lower mortality
compared with sulfonylurea use in the base case (adjusted hazard ratio O
ntre
al So
doi:10.1016/j.jval.2011.08.005aHR] 0.88, 95% confidence interval [CI] 0.78–0.99) and the nonformulary
imulations. The special authorization simulations demonstrated, how-
ver, an increasing relative mortality hazard of metformin versus sulfo-
ylurea exposure: aHR 0.96, 95% CI 0.96–0.97 and aHR 1.34, 95% CI 1.31–
.37, for 10%and50%delays in coverage capture respectivelywhen50%of
etformin users weremisclassified. Age-dependent drug coverage had a
ariable impact on mortality risk compared with the base-case cohort;
owever, a new-user simulation with a 1-year washout revealed consis-
ent results to the base-case analysis. Conclusion: Restrictive drug cov-
rage policies may result in substantial drug exposure misclassification,
otentially severely biasing the results of drug-outcome relationships us-
ng administrative databases.
eywords: bias, formularies, mortality, pharmaceutical policy, phar-
acoepidemiology simulation.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Administrative claims databases are commonly used for phar-
macoepidemiologic studies assessing the relationship between
drug exposures and health outcomes [1,2]. Like any epidemiologic
study, valid results from studies based on administrative claims
rely on accurate classification of disease state [3] and drug expo-
sure [4]. Misclassification bias may result in spurious conclusions
of benefit or harm. Potential sources of drug exposure misclassifi-
cation that are well known include nonadherence [5], over-the-
counter drug exposure [6], and free samples [7].
Although often overlooked, another potential source of drug
exposure misclassification is restrictive drug coverage policies [8].
Administrative drug databases commonly capture drug dispensa-
tion data through an electronic claims system, whereby the only
drugs captured are those that are either widely available on for-
mulary or only covered for those patientswhomeet special autho-
rization criteria (i.e., pre-specified clinical criteria) [9]. In other
* Address correspondence to: Dean T. Eurich, 2-040 Li Ka Shing Ce
AB T6G 2E1, Canada.
E-mail: deurich@ualberta.ca.
1098-3015/$36.00 – see front matter Copyright © 2012, Internation
Published by Elsevier Inc.words, each time a pharmacist processes and dispenses a pre-
scription specific details (e.g., drug name, dosage, quantity, price)
are sent to the payer via an electronic system; however, informa-
tion is only collected by the payer if the product is included in the
payer’s formulary. Although some administrative databases cap-
ture all drugs irrespective of drug coverage, this is the exception
rather than the norm. Drug policies that limit coverage through
nonformulary status or “special authorization” criteria for cover-
age are common cost-containmentmechanisms employed by sin-
gle party payers to guide prescribing [10,11]. However, to the ex-
tent that drugs with restrictive coverage policies are still used in
the population, but not captured in administrative databases,
these policies have the potential to result in drug exposure mis-
classification in pharmacoepidemiologic studies [8]. For example,
an individual’s drug exposure may not be captured if they choose
to pay for the medication “out-of-pocket” or have a private (non-
government) drug coverage plan [12]. This may occur over the
entire drug exposure period (i.e., never captured in the adminis-
for Health Research Innovation, University of Alberta, Edmonton,
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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192 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 1 9 1 – 1 9 7trative data) or may change over time, depending on the nature of
the policy (e.g., policy changed from restrictive coverage to full
coverage, or a patient passes a certain age threshold and becomes
eligible for coverage).
Thus, we designed this study to quantify the potential degree
of bias resulting from exposure misclassification due to a policy
restricting drug coverage. Specifically, we provide three simula-
tions that represent the potential consequences of restrictive drug
policies for pharmacoepidemiologic studies and measure the im-
pact of varying degrees of both drug categorymisclassification and
person-time exposuremisclassification on estimates obtained us-
ing administrative data.
Methods
Population and setting
The data sources and population studied were previously dis-
cussed in detail [13]. Briefly, 12,272 new-users of metformin or a
sulfonylurea were identified between January 1, 1991 and Decem-
ber 31, 1996 using the administrative databases of Saskatchewan
Health. Individuals were prospectively followed to the first occur-
rence of death, termination of Saskatchewan Health coverage, or
December 31, 1999, providing amaximum follow-up of 9 years [13].
Saskatchewan Health provides universal health coverage to its
approximately one million residents with the exception of federal
inmates, Royal Canadian Mounted Police, and members of the
armed forces (1% of the population). All health beneficiaries re-
gardless of age are eligible for prescription drug coverage except
those who receive these benefits through the federal government
(primarily First Nations, 9% of the population). Both metformin
and glyburide were listed in the provincial formulary with unre-
stricted coverage for the entire study period [14].
Patients who are new users of these antidiabetic agents were
categorized into mutually exclusive groups and followed from
their first dispensation date (index date) of an oral antidiabetic
therapy: 1626 (13%) were treated with metformin monotherapy,
4730 (39%) with sulfonylurea monotherapy, and 5916 (48%) were
treated with combination of sulfonylurea andmetformin therapy.
As previously reported, metformin monotherapy was associated
with lower all-cause mortality compared with sulfonylurea ther-
apy [13]. Ethical approval was obtained from the Health Ethics
Research Board of the University of Alberta.
Exposure misclassification simulations
For the purposes of this article, we reanalyzed the association
between metformin use and all-cause mortality under varying
amounts of exposuremisclassification. Specifically, we conducted
simulations to mimic potential consequences of three common
restrictive drug policies, which are non-formulary status, special
authorization, and age-based restrictions.We chosemetformin as
our “policy drug” because there was little or no exposure misclas-
sification of metformin in our original cohort study because it was
listed as a full benefit on the formulary in Saskatchewan through-
out the years of our study. Likewise, sulfonylurea use consisted
almost exclusively of glyburide andwas also listed as a full benefit
during this period in Saskatchewan.
In our nonformulary and special authorization simulations, we
randomly selected 0% (i.e., base case), 10%, 25%, and 50% of all
patients taking metformin to be subject to the hypothetical drug
policy and therefore have their drug exposure misclassified. Ran-
dom selection was conducted using a uniform random variable
generator in Stata SE version 11.2 (StataCorp LP, College Station,
TX) statistical software. Indeed, these simulations represent a re-
alistic approximation of the degree of potential drug exposure
misclassification. For example, a recent study reported that 70%of thiazolidinedione users were receiving therapy and were not
captured in a dataset limited to provincial claims only, due to a
special authorization policy resulting in the use of third party in-
surance or out of pocket payment for the medications [15].
Our first policy simulation is perhaps the simplest case of a
estrictive drug policy – a nonformulary drug, where exposure oc-
urred but the administrative claims database failed to capture
his via claimed dispensations. Thus, randomly selected individ-
als who were originally receiving metformin as monotherapy
ere reclassified as nonexposed and therefore removed from
nalyses (i.e., analysis comparing metformin vs. sulfonylurea but
ould be included in a “no use” comparison) for their entire fol-
ow-up. For metformin use in combination with sulfonylureas, in-
ividuals were reclassified as sulfonylurea monotherapy users.
Our second simulation is an example of a “special authoriza-
ion” drug use policy, whereby an initial period of exposure may
ccur (e.g., through private insurance or out-or-pocket), but is not
aptured within the claims databases until specific coverage cri-
eria have been met. As a result, a patient’s actual or true number
f person-years exposed to the policy drug would be underesti-
ated due to the delayed capture of exposure. To simulate this
blind period” while individuals fulfilled coverage criteria, we de-
ayed themetformin index date for randomly selected individuals
y 10%, 25%, and 50% of the total exposure time between an indi-
idual’s first metformin dispensation and exit from the cohort. As
n the previous simulation, we randomly selected 10%, 25%, and
0% of individuals to be subject to the hypothetical policy.
We intentionally introduced drug exposuremisclassification in
random fashion for the above simulations because there may be
everal reasons why specific drugs will not be fully reimbursed.
ge-based criteria, however, are often used to define eligibility
riteria for drug insurance plans, of which seniors are the most
ommon beneficiary group. We therefore, ran a third simulation
hereby we considered any drug exposure prior to age 66 not
vailable within the administrative database (even though the
askatchewan Health datasets we used do capture prescriptions
n younger patients). Drug exposure prior to age 66was reclassified
s nonexposed. Individualswho died orwere censored prior to age
6were therefore excluded from the analysis. For individuals with
n oral antidiabetic index date prior to their 66th birthday, we
hifted the index date to the date they turned 66 years of age to
epresent the first captured dispensation within the age based
estrictive drug policy.
In summary, we varied the number of people exposed to met-
ormin (simulation one) and the time of metformin initiation due
o specific coverage (simulation two) or age based criteria (simu-
ation three).
Statistical analysis
Cox proportional hazards regression models were used to assess
the relationship betweendrug exposure andmortality. Individuals
were considered exposed to metformin or sulfonylurea therapy
from the date of their first dispensation until the date they died,
left the province, or December 31, 1999, whichever occurred earli-
est.We adjusted the analyses for baseline age, sex, chronic disease
score [16], and insulin use, as previously published [13]. To esti-
mate the adjusted hazard ratios (aHR) and confidence intervals
(CI), we used 1000 bootstrap samples for the nonformulary and
special authorization simulations. For these simulations, we re-
port the mean HR and the 2.5th and 97.5th percentiles of the 1000
repetitions. For the age-dependent coverage policy simulation, we
report HR and 95% CI based on the eligible cohort 66 years and
older.We used the HR point estimate from the base-case cohort as
our reference standard to assess the degree of potential bias.
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Cohort characteristics
We identified 12,272 patients who were new users of oral antidia-
betic agents. Mean age was 64 (SD 14) years, 55% were male, and
51% had a history of cardiovascular disease. Overall, 2681 (21.9%)
individuals died over amean follow-up period of 5.1 (SD 2.2) years.
Over the entire observation period, 4730 (38.5%) individuals were
exposed to sulfonylurea monotherapy, 1626 (13.3%) individuals
were exposed to metformin monotherapy, and 5916 (48.2%) indi-
viduals were exposed to combination therapy (i.e., metformin and
sulfonylurea).
In our base case with 0% misclassification, there were 10,286
person-years of exposure for metformin use and 32,969 person-
years for sulfonylurea use. Compared with sulfonylurea mono-
therapy exposure, metformin monotherapy exposure was associ-
ated with a 10% absolute reduction (317 [20%] versus 1440 [30%])
and 12% relative risk reduction ofmortality; aHR 0.88 (95% CI 0.78–
0.99)]. Tables 1, 2, 3 include the person-years follow-up, mortality
ates, and misclassified person-years for the base case and simu-
ation cohorts.
Simulation one – use of nonformulary drug
In this scenario the amount of person-time lost for the 10% to 50%
misclassification of metformin monotherapy use ranged from
1017 person-years to 5211 person-years. Similarly, the apparent
proportion of sulfonylurea monotherapy person-time increased
from 1904 person-years to 9690 person-years (because combina-
tion users were now misclassified as sulfonylurea monotherapy
users) compared with the original cohort (Table 1). Figure 1 illus-
rates the adjusted point estimates and their corresponding 95%CI
ithin the metformin exposure and combination exposure cate-
ories compared with sulfonylurea monotherapy for 10%, 25%,
nd 50%misclassification of metformin users. Compared with the
ull cohort without misclassification, exposure misclassifications
f 10%, 25%, and 50% for metformin users overestimated the ben-
ficial effect of metformin monotherapy compared with sulfonyl-
reamonotherapy [i.e., decreased the relative HR] by 2% [aHR 0.86;
Table 1 – Person-years of follow-up and mortality rates wi
1 (nonformulary policy) with no misclassification, and 10%
Variables
Base-case cohort (no misclassification of metformin users)
Person-years follow-up
Mortality rate per 1000 py (95% CI)
Person-years misclassified
10% of metformin users randomly misclassified
Person-years follow-up
Mortality rate per 1000 py (95% CI)
Person-years misclassified
25% of metformin users randomly misclassified
Person-years follow-up
Mortality rate per 1000 py (95% CI)
Person-years misclassified
50% of metformin users randomly misclassified
Person-years follow-up
Mortality rate per 1000 py (95% CI)
Person-years misclassified
95% CI, 95% confidence interval; py, person-years.5% CI 0.83–0.89], 3% [aHR 0.85; 95% CI 0.79–0.89], and 6% [aHR0.82; 95% CI 0.73–0.91]. A similar trend was observed for exposure
to combination therapy compared with sulfonylurea mono-
therapy whereby the relative hazard estimate decreased by 3%
(aHR 1.34; 95% CI 1.29–1.39), 6% (aHR 1.31; 95% CI 1.24–1.38), and
11% (aHR 1.26; 95% CI 1.16–1.36) compared with the base-case es-
timate (aHR 1.37; 95% CI 1.26–1.50).
Simulation two – special authorization drugs
In simulation two, the number of individuals was identical to
the base-case cohort (n  12,272), however, drug exposure mis-
classification was induced by shifting exposure time for a ran-
dom selection of individuals dispensed metformin in an at-
tempt to mimic a special authorization drug policy. The amount
of timemisclassified due to proportional shifts of person-time is
shown in Table 2. As expected, there is more person-time mis-
classification as the index date for metformin therapy is shifted
more dramatically. The amount of misclassified exposure time
ranged from 137 person-years to 3021 person-years for met-
formin and 154 person-years to 4429 person-years for sulfonyl-
urea monotherapy.
Figure 2 depicts the adjusted point estimates and 95% CIs for
metformin monotherapy (Fig. 2A) and combination therapy (Fig.
2B). Unlike simulation one where greater misclassification re-
sulted in minimal changes in point estimates, the bias introduced
due to delayed observation of exposure in the administrative data
results in a negative shift (i.e., potentially beneficial to potentially
harmful) in the point estimates for metformin therapy in all mis-
classification schemes. Indeed, when a random sample of 10%,
25%, and 50% of individuals exposed to metformin were selected
and their index date was shifted by 50% of their metformin expo-
sure time, the apparent benefits decreased by 7% (aHR 0.95; 95% CI
0.94–0.96), 19% (aHR 1.07; 95% CI 1.06–1.09), and 46% (aHR 1.34;
95% CI 1.31–1.37), respectively. Similar results were found when
comparing combination therapy with sulfonylurea monotherapy
(Fig. 2B).
Simulation three – age-dependent coverage policy
A total of 4791 (39%) individuals were excluded in the age-depen-
drug exposure groups of interest for simulation
, and 50% random misclassification of metformin users.
Drug exposure groups
tformin
otherapy
Sulfonylurea
monotherapy
Combination
metformin/sulfonylurea
therapy
10,286 32,969 19,544
(28–34) 44 (42–46) 47 (44–50)
0 0 0
9,269 34,873 17,640
(27–34) 44 (42–46) 47 (44–50)
–1,017 1,904 –1,904
7,683 37,776 14,737
(28–36) 45 (43–48) 46 (43–50)
–2,603 4,807 –4,807
5,075 42,659 9,853
(37–37) 45 (43–47) 46 (41–50)
–5,211 9,690 –9,690thin
, 25%
Me
mon
31
30
32
32dent coverage policy simulation because they died or were cen-
Table 2 – Person-years of follow-up and mortality rates within drug exposure groups of interest for simulation 2 (special authorization policy) with no
misclassification, and 10%, 25%, and 50% random misclassification of metformin users. Index dates of misclassified metformin users are shifted 10%, 25%, and 50%
of an individual’s total follow-up time.
Variables Drug exposure groups
Metformin monotherapy Sulfonylurea monotherapy Combinationmetformin/sulfonylurea
therapy
10% index
date shift
25% index
date shift
50% index
date shift
10% index
date shift
25% index
date shift
50% index
date shift
10% index
date shift
25% index
date shift
50% index
date shift
Base-case cohort (no misclassification
of metformin users)
Person-years follow-up 10,286 10,286 10,286 32,969 32,969 32,969 19,544 19,544 19,544
Mortality rate per 1000 py (95% CI) 31 (28–34) 31 (28–34) 31 (28–34) 44 (42–46) 44 (42–46) 44 (42–46) 47 (44–50) 47 (44–50) 47 (44–50)
Person-years misclassified 0 0 0 0 0 0 0 0 0
10% of metformin users randomly
misclassified
Person-years follow-up 10,149 9,960 9,690 33,123 33,373 33,833 19,389 19,140 18,679
Mortality rate per 1000 py (95% CI) 31 (28–35) 32 (29–36) 33 (29–37) 43 (41–46) 43 (41–45) 43 (40–45) 48 (45–51) 48 (45–51) 49 (46–53)
Person-years misclassified –137 –326 –596 154 404 864 –154 –404 –864
25% of metformin users randomly
misclassified
Person-years follow-up 9,940 9,464 8,768 33,363 33,999 35,155 19,149 18,513 17,357
Mortality rate per 1000 py (95% CI) 32 (29–36) 33 (30–37) 36 (33–40) 43 (41–45) 42 (40–45) 41 (39–43) 48 (45–51) 50 (47–53) 53 (50–57)
Person-years misclassified –346 –822 –1,518 394 1,030 2,186 –394 –1,030 –2,186
50% of metformin users randomly
misclassified
Person-years follow-up 9,594 8,651 7,265 33,767 35,060 37,398 18,745 17,453 15,114
Mortality rate per 1000 py (95% CI) 33 (30–37) 37 (33–41) 44 (39–49) 43 (40–45) 41 (39–43) 39 (37–41) 49 (46–53) 53 (50–56) 61 (57–65)
Person-years misclassified –692 –1,635 –3,021 798 2,091 4,429 –798 –2,091 –4,429
95% CI, 95% confidence interval; py, person-years.
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195V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 1 9 1 – 1 9 7sored prior to their 66th birthday (Table 3). Of the 7481 individuals
included, 3252 (43.4%) were patients receiving sulfonylureamono-
therapy, 940 (12.6%) were patients receiving metformin mono-
therapy, and 3289 (44.0%) were patients receiving combination
(metformin/sulfonylurea) therapy. The relationship betweenmet-
formin monotherapy (aHR 0.89; 95% CI 0.78–1.01) compared with
sulfonylurea monotherapy was consistent in magnitude and di-
rection with the base-case cohort. However, combination therapy
(aHR 1.18; 95% CI 1.08–1.29) was associated with a 19% absolute
lower hazard ratio compared with the base-case cohort. The ma-
jority of individuals started their oral antidiabetic agents after
their 66th birthday and, therefore, did not have their index date
shifted. On average, an individual’s index date shifted 11% of their
total follow-up time. There were 1694 (22%) individuals who
started an oral antidiabetic agent before their 66th birthday. For
these individuals their index date was shifted 1100 (SD 724) days
on average, representing 49% of their total follow-up time. When
Table 3 – Person-years of follow-up and mortality rates wi
dependent coverage policy) with no misclassification, and
Variables
Base-case cohort (no misclassification of metformin users)
Person-years follow-up
Mortality rate per 1000 py (95% CI)
Person-years misclassified
Metformin use misclassified based on age
Person-years follow-up
Mortality rate per 1000 py (95% CI)
Person-years misclassified
95% CI, 95% confidence interval; py, person-years.
Fig. 1 – Adjusted hazard ratios for the relationship between
amounts of metformin drug exposure misclassification base
users. *Adjusted for age at index date, sex, chronic disease scorewe excluded patients takingmetformin or a sulfonylurea between
their 65th and 66th birthday, a new-users analysis indicated con-
sistent results to our primary analysis for both metformin mono-
therapy (aHR 0.90; 95% CI 0.79–1.03) and combination therapy
(aHR 1.42; 95% CI 1.29–1.56).
Discussion
Our analyses demonstrate that common restrictive drug coverage
policies may introduce misclassification of drug exposure in ad-
ministrative claims databases and bias reported drug-outcome as-
sociations. Our “nonformulary” simulation demonstrated mini-
mal changes in the point estimate associated with our
hypothetical policy drugmetformin comparedwith sulfonylureas,
suggesting an over-estimated benefit for metformin by 2% to 6%,
depending on the proportion of metformin users affected. Our
drug exposure groups of interest for simulation 3 (age-
ing of index date based on an individual’s 66th birthday.
Drug exposure groups
tformin
otherapy
Sulfonylurea
monotherapy
Combination
metformin/sulfonylurea
therapy
10,286 32,969 19,544
(28–34) 44 (42–46) 47 (44–50)
0 0 0
4,821 18,423 9,307
(48–61) 68 (64–72) 84 (79–91)
–5,465 –14,546 –10,237
iabetic use and all-cause mortality according to varying
a hypothetical nonformulary simulation for metforminthin
shift
Me
mon
31
54antid
d on, and insulin use.
196 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 1 9 1 – 1 9 7“special authorization” simulation, however, demonstrated an ef-
fect estimate that changed the direction of the association from
one of apparent benefit to one of apparent harm. As expected, the
more individuals and person-time in which drug exposure was
misclassified, the larger the observed bias. Similarly, our age-de-
pendent coverage policy simulation suggested that substantial
bias could result if exposure time prior to age 65 years is ignored.
When we restricted our age-dependent coverage simulation to
newusers, however, risk estimateswere consistent with our base-
case analysis.
There are several examples of restrictive drug policies thatmay
result in a period of exposure misclassification within the admin-
istrative database, including over-the-counter medications, drug
samples, special authorizations, exceptional drug status, and lim-
ited use, among others. Although the extent to which over-the-
counter medications and free samples induces bias is relatively
limited when studying rare outcomes [6,7], the extent to which
common restrictive drug coverage policies such as special autho-
Fig. 2 – (A) Adjusted hazard ratios for the relationship
between metformin monotherapy and all-cause mortality
according to varying amounts of metformin drug exposure
misclassification based on a hypothetical special
authorization simulation for metformin users. (B) Adjusted
hazard ratios for the relationship between combination
(metformin/sulfonylurea) therapy and all-cause mortality
according to varying amounts of metformin drug exposure
misclassification based on a hypothetical special
authorization simulation for metformin users. *Adjusted for
age at index date, sex, chronic disease score, and insulin use.rization may induce bias is unknown. Our simulations provide arange of estimates for the potential magnitude of such biases.
Perhaps themost important implication of our findings is that the
misclassification bias arising from a restrictive drug policymay be
severe enough to potentially change the direction of a drug-out-
come relationship. Therefore beneficial medications may be spu-
riously reported as neutral or harmful and harmful medications
may appear beneficial or neutral. One option to avoid this bias is to
restrict study hypotheses to include only formulary medications
or to limit evaluation to periods when all drugs of interest were on
formulary; this becomes problematic, however, when coverage
policies change over time. Delisting and special authorization pol-
icies are often dynamic and thereby may create apparently unex-
posed periods of follow-up time in administrative databaseswhen
subjects are in reality exposed.
There is little published evidence on the potential extent and
direction to which “drug policy” induces misclassification bias. In
one study it was estimated that 69% of patients exposed to a thia-
zolidinedione would have been misclassified if the analysis were
limited to only those patients with prescriptions captured in the
provincial administrative database [15]. If all drugs of interest are
affected equally (nondifferential misclassification) by the policy,
the results are generally biased towards the null. When differen-
tial misclassification occurs (i.e., only a subset of drugs affected by
policy) the direction of bias is unpredictable [17]. Moreover, the
policy drug may be disproportionally affected because of factors
related to both the policy and the outcome. For example, younger
patients with a higher socioeconomic status are more likely to be
pay “out of pocket” or have additional private insurance and may
be both less likely to experience the health outcome and be im-
pacted by a restrictive drug coverage policy.
The method in which data is collected is central to the “drug
policy bias” that we have described and demonstrated using a real
world dataset. The fact that only drugs paid for by a particular drug
plan or group of plans, whether governmental or private, are in-
cluded in many administrative databases is the root of the mis-
classification. In an effort to minimize drug exposure misclassifi-
cation, it is imperative that all drugs dispensed be captured. This is
possible for all prescription medications because they are elec-
tronically processed and is in fact already the case for some pub-
licly funded health care systems (e.g., British Columbia and Man-
itoba in Canada). Recent examples in the literature suggest that
researchers acknowledge restrictive drug coverage policies as a
potential limitation in their data; however, quantification of this
bias is absent. For example, Lipscombe et al. [18] evaluated the
effect of thiazolidinediones on heart failure, acute myocardial in-
farction, and mortality. During the period of drug exposure, thia-
zolidinedioneswere only covered by the Ontario’s public drug pro-
gram if a physician completed a prior authorization form
indicating the pre-specified coverage criteria had been met. The
authors acknowledge this and report that 10% to 13% of coverage
requests were not approved during their study period; however, it
is unknown whether those denied approval were exposed to thia-
zolidinediones by purchasing these medications out of pocket or
via private insurance, or if a subset of the population who never
applied for coverage were also exposed.
Limitations
Although we have demonstrated a potential bias present in the
pharmacoepidemiology literature using real world data, our study
does have limitations. First, our hypothetical drug policy example
was that of a known beneficial drug evaluating only a single out-
come; however, our results likely apply equally to a drug reported
to have a negative effect on health outcomes or multiple endpoint
studies. Second, we only evaluated a two-drug scenario. More
complex drug comparisons of three ormore drugsmay also occur,
especially in chronic diseases with multiple treatment options,
and provide a greater propensity for drug exposure misclassifica-
197V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 1 9 1 – 1 9 7tions within multiple exposure categories and unpredictable ef-
fects. Third, the degree of misclassification introduced within the
simulations was arbitrary ranging from 10% to 50% but is likely
indicative of real-world populations, as published examples illus-
trate [15]. Moreover, we have demonstrated that the results are
highly sensitive to the degree of person-timemisclassified. Fourth,
our administrative data contained limited information on poten-
tial confounders, especially clinical variables (e.g., hemoglobin
A1C, blood pressure, smoking status, or lipid values); however, we
selected individuals tomisclassify in a randommanner and there-
fore residual confounding is unlikely to explain our results. Last,
we used a real-world cohort of individuals to represent the “true”
relationship between metformin and all-cause mortality. Al-
though a similar protective effect ofmetformin has been observed
in randomized controlled trials and other observational studies,
our results may not be generalizable to other cohorts in which the
metformin-mortality relationship is substantially different.
Conclusions
In conclusion, we have illustrated the potential impact of restric-
tive drug coverage policies creating time periods in which expo-
sure to a particular drug (in this case metformin) may still have
occurred but was not captured by an administrative drug plan
database. Our results suggest that the validity of epidemiologic
studies using administrative databases that evaluate drug-out-
come relationships in drugs subject to restrictive coverage polices
may be compromised because of drug exposure misclassification.
Thus, better reporting of drug policies existent in a geographic
locale during the years of study are required to fully interpret re-
sults of pharmacoepidemiology studies using administrative da-
tabases from that locale.
Acknowledgements
This study is based in part on de-identified data provided by the
Saskatchewan Ministry of Health. The interpretation and conclu-
sions contained herein do not necessarily represent those of the
Government of Saskatchewan or the Saskatchewan Ministry of
Health.
Source of financial support: Mr. Gamble receives salary support
through a full-time Health Research Studentship from Alberta In-
novates – Health Solutions (AIHS) and a Canada Graduate Schol-
arship from the Canadian Institutes of Health Research (CIHR). Dr.
Eurich is a Population Health Investigator with AIHS and a New
Investigator with the CIHR. Dr. McAlister is a Health Scholar with
AIHS. Dr. Johnson is a SeniorHealth ScholarwithAIHS andCanada
Research Chair in Diabetes Health Outcomes. This study wasfunded in part by a CIHR Team Grant to the Alliance for Canadian
Health Outcomes Research in Diabetes (ACHORD) (reference #:
OTG-88588), sponsored by the CIHR Institute of Nutrition, Metab-
olism and Diabetes (INMD). The authors have no conflicts of inter-
est to declare.
R E F E R E N C E S
[1] Ray WA. Improving automated database studies. Epidemiology 2011;
22:302–4.
[2] Rawson NS, Downey W, Maxwell C, West R. 25 Years of
pharmacoepidemiology innovation: the Saskatchewan Health
administrative databases. J Popul Ther Clin Pharmacol 2011;18:e245–9.
[3] Manuel DG, Rosella LC, Stukel TA. Importance of accurately
identifying disease in studies using electronic health records. BMJ
2010;341:c4226.
[4] Stang A. Appropriate epidemiologic methods as a prerequisite for
valid study results. Eur J Epidemiol 2008;23:761–5.
[5] Van Staa T, Abenhain L, Leufkens H. A study of the effects of exposure
misclassification due to the time-window design in
pharmacoepidemiologic studies. J Clin Epidemiol 2003;42:183–9.
[6] Yood MU, Campbell UB, Rothman KJ, et al. Using prescription claims
data for drugs available over-the-counter (OTC). Pharmacoepidemiol
Drug Saf 2007;16:961–8.
[7] Jacobus S, Schneeweiss S, Chan KA. Exposure misclassification as a
result of free sample drug utilization in automated claims databases
and its effect on a pharmacoepidemiology study of selective COX-2
inhibitors. Pharmacoepidemiol Drug Saf 2004;13:695–702.
[8] Schneeweiss S, Avorn J. A review of uses of health care utilization
databases for epidemiologic research on therapeutics. J Clin Epidemiol
2005;58:323–37.
[9] Strom BL. Overview of automated databases in pharmacoepidemiology.
In: Strom BL, ed., Pharmacoepidemiology (4th ed.). Chichester: JohnWiley
& Sons, 2005.
[10] Almarsdottir A, Traulsen J. Rational use of medicines – an important
issue in pharmaceutical policy. Pharm World Sci 2005;27:76–80.
[11] Boucher BA. Formulary decisions: then and now. Pharmacotherapy
2010;30:35S–41S.
[12] Paterson JM, Suleiman A, Hux JE, Bell C. How complete are drug
history profiles that are based on public drug benefit claims? Can
J Pharmacol 2008;15:e106–16.
[13] Johnson JA, Majumdar SR, Simpson SH, Toth EL. Decreased mortality
associated with the use of metformin compared with sulfonylurea
monotherapy in type 2 diabetes. Diabetes Care 2002;25:2244–8.
[14] Downey W, Stang M, Beck P, et al. Health services databases in
Saskatchewan. In Strom B, ed., Pharmacoepidemiology (4th ed.).
Chichester: John Wiley & Sons, 2005.
[15] Dormuth C, Carney G, Carleton B, et al. Thiazolidinediones and
fractures in men and women. Arch Intern Med 2009;169:1395–402.
[16] Von Korff M, Wagner EH, Saunders K. A chronic disease score from
automated pharmacy data. J Clin Epidemiol 1992;45:197–203.
[17] Rothman KJ, Greenland S, Lash TL. Validity in epidemiologic studies.
In: Rothman KJ, Greenland S, Lash TL, eds., Modern Epidemiology (3rd
ed.). Philadelphia: Lippincott Williams & Wilkins, 2008.
[18] Lipscombe LL, Gomes T, Lévesque LE, et al. Thiazolidinediones and
cardiovascular outcomes in older patients with diabetes. JAMA 2007;
298:2634–43.
